In contrast to reports of lower frequency of peripheral CD4+ T cells in breast cancer patients, almost all studies have found no significant difference in the frequency of peripheral CD19+ B cells between cancer patients and healthy controls. The gene discussed is CD19; the disease is breast cancer.